Caspr Bio

Based in San Francisco, California, Caspr Bio is a biotechnology company that develops rapid, portable CRISPR-based diagnostic test kits using novel Cas proteins sourced from extremophiles. The seed-stage enterprise operates with fewer than 25 employees and has filed two patents for its high-temperature isothermal amplification technology. The firm targets infectious disease testing for conditions like COVID-19, Dengue, and antimicrobial resistance, forming strategic research and development partnerships with organizations such as Renegade.bio. Backed by the IndieBio accelerator, the company raised $150,000 in seed venture capital funding and generated under $5 million in revenue before being acquired by a Fortune 100 corporation. Following the acquisition, key personnel transitioned to Amazon to support the retail giant's internal diagnostic testing initiatives for its workforce. Caspr Bio was founded in 2018 by Franco Goytia, Carla Giménez, and Lucia Curti.

High-Level Overview

CASPR Biotech is a seed-stage biotech company founded in 2018 that develops rapid, portable molecular diagnostics using novel CRISPR-Cas enzymes discovered from extremophiles.[1][2][3] It targets infectious diseases and antimicrobial resistance (AMR), offering kits like the Caspr Lyo-CRISPR SARS-CoV-2 test for COVID-19 detection in under 60 minutes with minimal equipment.[2][3] The company serves healthcare professionals and has pivoted from early cancer therapy concepts to diagnostics, raising $150K from investors including IDB Lab, SOSV, and IndieBio; it was acquired by a Fortune 100 company (likely Amazon, which hired its cofounders for COVID testing).[1][3]

Growth momentum included rapid COVID-19 response post-IndieBio graduation, with scientists relocating to San Francisco for test development and subsequent acquisition enabling scaled production of cheap CRISPR-based kits.[3]

Origin Story

CASPR Biotech emerged from IndieBio, an SOSV accelerator, when founders—including CEO Franco Goytia and Chief Strategy Officer Carla Gimenez—traveled to extreme environments like high-altitude mountains and volcanoes in Argentina to discover novel, temperature-resistant Cas proteins amid CRISPR IP constraints.[3] Founded in 2018 in Barreiras, Brazil (with later San Francisco operations), the idea stemmed from bypassing "CRISPR wars" by sourcing undiscovered enzymes from extremophiles for robust diagnostics.[1][3]

Pivotal moments included COVID-19 hitting one month after graduation, prompting 15 scientists to live communally in San Francisco to build tests; this led to Amazon hiring key team members for Project Artemis (employee COVID testing at scale) and full acquisition by a Fortune 100 firm.[1][3]

Core Differentiators

• Novel CRISPR Enzymes: Sources unique, IP-free Cas proteins from extremophiles for temperature-stable, rapid diagnostics, enabling portable kits without heavy equipment.[2][3]
• Speed and Simplicity: Delivers results in <60 minutes for infectious diseases/AMR/COVID-19, using lyophilized (Lyo-CRISPR) tech submitted for FDA EUA; minimal external needs differentiate from lab-bound tests.[1][2]
• Portability and Cost: Focuses on cheap, field-deployable solutions for high-risk settings, outperforming traditional PCR in accessibility.[3]
• Proven Traction: Filed 2 biotech/DNA/genetic engineering patents; rapid COVID pivot led to Fortune 100 acquisition and Amazon integration.[1][3]

(Note: Distinct from Casprtech.com's NC2I air/surface disinfection systems, which use unrelated photocatalytic tech.[4])

Role in the Broader Tech Landscape

CASPR Biotech rides the CRISPR diagnostics wave, accelerating post-COVID demand for decentralized, point-of-care testing amid antimicrobial resistance crises and pandemic preparedness.[1][2][3] Timing aligned perfectly with 2020's testing shortages, positioning it as a key player in biotech's shift from gene editing to accessible diagnostics via novel Cas variants.

Market forces like IP bottlenecks in mainstream CRISPR favored its extremophile sourcing, influencing the ecosystem by proving accelerator models (e.g., IndieBio) can yield acquisition exits and scale via Big Tech (Amazon/Fortune 100).[3] It advances global health equity by enabling low-resource diagnostics in Brazil/Latin America hubs.[1]

Quick Take & Future Outlook

Post-acquisition, CASPR Biotech scales CRISPR kits for broader infectious diseases, leveraging Fortune 100 resources for global distribution.[3] Trends like AI-enhanced enzyme discovery and multiplex testing will amplify its edge, potentially expanding to AMR surveillance and biothreat detection.

Its influence may evolve from startup innovator to embedded tech in enterprise health screening, tying back to its origins: extremophile hunting unlocked diagnostics that met a global crisis head-on, redefining rapid testing's potential.